Development of an allele-specific real-time PCR assay for discrimination and quantification of p63 R279H mutation in EEC syndrome

V. Barbaro, S. Ferrari, D. Ponzin, M. Parekh, E. Di Iorio, L. Confalonieri, I. Vallini, G. Mantero, C.E. Willoughby

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The ectrodactyly-ectodermal dysplasiaclefting syndrome is a rare autosomal dominant disorder caused by heterozygous mutations in the p63 gene, a transcription factor belonging to the p53 family. The majority of cases of ectrodactyly-ectodermal dysplasia syndrome are caused by de novo mutations and are therefore sporadic in approximately 60% of patients. The substitution of arginine to histidine (R279H), due to a c.836G>A mutation in exon 7 of the p63 gene, represents 55% of the identified mutations and is considered a mutational hot spot. A quantitative and sensitive real-time PCR was performed to quantify both wild-type and R279H alleles in DNA extracted from peripheral blood and RNA from cultured epithelial cells. Standard curves were constructed for both wild-type and mutant probes. The sensitivity of the assay was determined by generating serial dilutions of the DNA isolated from heterozygous patients (50% of alleles mutated) with wild-type DNA, thus obtaining decreasing percentages of p63 R279H mutant allele (50%, 37.5%, 25%, 12.5%, 10%, 7.5%, 5%, 2.5%, and 0.0%). The assay detected up to 1% of the mutant p63. The high sensitivity of the assay is of particular relevance to prenatal diagnosis and counseling and to detect therapeutic effects of drug treatment or gene therapy aimed at reducing the amount of mutated p63. © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)38-45
Number of pages8
JournalJournal of Molecular Diagnostics
Volume14
Issue number1
DOIs
Publication statusPublished - 01 Jan 2012

Fingerprint

Real-Time Polymerase Chain Reaction
Alleles
Mutation
DNA
Ectodermal Dysplasia
Molecular Pathology
Therapeutic Uses
Prenatal Diagnosis
Histidine
Genetic Therapy
Genes
Arginine
Counseling
Exons
Cultured Cells
Transcription Factors
Epithelial Cells
RNA
Drug Therapy
Ectrodactyly-cleft lip-palate syndrome

Cite this

Barbaro, V. ; Ferrari, S. ; Ponzin, D. ; Parekh, M. ; Di Iorio, E. ; Confalonieri, L. ; Vallini, I. ; Mantero, G. ; Willoughby, C.E. / Development of an allele-specific real-time PCR assay for discrimination and quantification of p63 R279H mutation in EEC syndrome. In: Journal of Molecular Diagnostics. 2012 ; Vol. 14, No. 1. pp. 38-45.
@article{9bd03dcd980a48489a6a17a07b77347f,
title = "Development of an allele-specific real-time PCR assay for discrimination and quantification of p63 R279H mutation in EEC syndrome",
abstract = "The ectrodactyly-ectodermal dysplasiaclefting syndrome is a rare autosomal dominant disorder caused by heterozygous mutations in the p63 gene, a transcription factor belonging to the p53 family. The majority of cases of ectrodactyly-ectodermal dysplasia syndrome are caused by de novo mutations and are therefore sporadic in approximately 60{\%} of patients. The substitution of arginine to histidine (R279H), due to a c.836G>A mutation in exon 7 of the p63 gene, represents 55{\%} of the identified mutations and is considered a mutational hot spot. A quantitative and sensitive real-time PCR was performed to quantify both wild-type and R279H alleles in DNA extracted from peripheral blood and RNA from cultured epithelial cells. Standard curves were constructed for both wild-type and mutant probes. The sensitivity of the assay was determined by generating serial dilutions of the DNA isolated from heterozygous patients (50{\%} of alleles mutated) with wild-type DNA, thus obtaining decreasing percentages of p63 R279H mutant allele (50{\%}, 37.5{\%}, 25{\%}, 12.5{\%}, 10{\%}, 7.5{\%}, 5{\%}, 2.5{\%}, and 0.0{\%}). The assay detected up to 1{\%} of the mutant p63. The high sensitivity of the assay is of particular relevance to prenatal diagnosis and counseling and to detect therapeutic effects of drug treatment or gene therapy aimed at reducing the amount of mutated p63. {\circledC} 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.",
author = "V. Barbaro and S. Ferrari and D. Ponzin and M. Parekh and {Di Iorio}, E. and L. Confalonieri and I. Vallini and G. Mantero and C.E. Willoughby",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.jmoldx.2011.07.008",
language = "English",
volume = "14",
pages = "38--45",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "1",

}

Barbaro, V, Ferrari, S, Ponzin, D, Parekh, M, Di Iorio, E, Confalonieri, L, Vallini, I, Mantero, G & Willoughby, CE 2012, 'Development of an allele-specific real-time PCR assay for discrimination and quantification of p63 R279H mutation in EEC syndrome', Journal of Molecular Diagnostics, vol. 14, no. 1, pp. 38-45. https://doi.org/10.1016/j.jmoldx.2011.07.008

Development of an allele-specific real-time PCR assay for discrimination and quantification of p63 R279H mutation in EEC syndrome. / Barbaro, V.; Ferrari, S.; Ponzin, D.; Parekh, M.; Di Iorio, E.; Confalonieri, L.; Vallini, I.; Mantero, G.; Willoughby, C.E.

In: Journal of Molecular Diagnostics, Vol. 14, No. 1, 01.01.2012, p. 38-45.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of an allele-specific real-time PCR assay for discrimination and quantification of p63 R279H mutation in EEC syndrome

AU - Barbaro, V.

AU - Ferrari, S.

AU - Ponzin, D.

AU - Parekh, M.

AU - Di Iorio, E.

AU - Confalonieri, L.

AU - Vallini, I.

AU - Mantero, G.

AU - Willoughby, C.E.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The ectrodactyly-ectodermal dysplasiaclefting syndrome is a rare autosomal dominant disorder caused by heterozygous mutations in the p63 gene, a transcription factor belonging to the p53 family. The majority of cases of ectrodactyly-ectodermal dysplasia syndrome are caused by de novo mutations and are therefore sporadic in approximately 60% of patients. The substitution of arginine to histidine (R279H), due to a c.836G>A mutation in exon 7 of the p63 gene, represents 55% of the identified mutations and is considered a mutational hot spot. A quantitative and sensitive real-time PCR was performed to quantify both wild-type and R279H alleles in DNA extracted from peripheral blood and RNA from cultured epithelial cells. Standard curves were constructed for both wild-type and mutant probes. The sensitivity of the assay was determined by generating serial dilutions of the DNA isolated from heterozygous patients (50% of alleles mutated) with wild-type DNA, thus obtaining decreasing percentages of p63 R279H mutant allele (50%, 37.5%, 25%, 12.5%, 10%, 7.5%, 5%, 2.5%, and 0.0%). The assay detected up to 1% of the mutant p63. The high sensitivity of the assay is of particular relevance to prenatal diagnosis and counseling and to detect therapeutic effects of drug treatment or gene therapy aimed at reducing the amount of mutated p63. © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

AB - The ectrodactyly-ectodermal dysplasiaclefting syndrome is a rare autosomal dominant disorder caused by heterozygous mutations in the p63 gene, a transcription factor belonging to the p53 family. The majority of cases of ectrodactyly-ectodermal dysplasia syndrome are caused by de novo mutations and are therefore sporadic in approximately 60% of patients. The substitution of arginine to histidine (R279H), due to a c.836G>A mutation in exon 7 of the p63 gene, represents 55% of the identified mutations and is considered a mutational hot spot. A quantitative and sensitive real-time PCR was performed to quantify both wild-type and R279H alleles in DNA extracted from peripheral blood and RNA from cultured epithelial cells. Standard curves were constructed for both wild-type and mutant probes. The sensitivity of the assay was determined by generating serial dilutions of the DNA isolated from heterozygous patients (50% of alleles mutated) with wild-type DNA, thus obtaining decreasing percentages of p63 R279H mutant allele (50%, 37.5%, 25%, 12.5%, 10%, 7.5%, 5%, 2.5%, and 0.0%). The assay detected up to 1% of the mutant p63. The high sensitivity of the assay is of particular relevance to prenatal diagnosis and counseling and to detect therapeutic effects of drug treatment or gene therapy aimed at reducing the amount of mutated p63. © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

UR - http://www.scopus.com/inward/record.url?partnerID=yv4JPVwI&eid=2-s2.0-84555178792&md5=c086702e58a166fca2e8373878fe94a2

U2 - 10.1016/j.jmoldx.2011.07.008

DO - 10.1016/j.jmoldx.2011.07.008

M3 - Article

C2 - 22056627

VL - 14

SP - 38

EP - 45

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 1

ER -